Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Perlegen Sciences logo — Uncovering genetic insights to elevate clinical decisions an...

Perlegen Sciences

Uncovering genetic insights to elevate clinical decisions and enhance patient outcomes.

Founded 2000 17 employees Series D Total: $154.00M Biotechnology, Health Care +1

General Information

Company Name Perlegen Sciences
Founded Year 2000
Employees 17
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Perlegen Sciences. To contact Perlegen Sciences, visit perlegen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Perlegen Sciences

Perlegen Sciences, established in 2000 and headquartered in Mountain View, California, focuses on leveraging genetic insights to aid physicians in making informed clinical decisions and enhancing patient outcomes. The company offers MammaPLUS, a breast cancer risk assessment tool that evaluates individual genetic and clinical risk for non-familial breast cancer, as well as the risk of developing invasive breast cancer. Additionally, Perlegen Sciences provides the Genotype Browser Website, allowing users to access and analyze genetic variation data from diverse human populations. In January 2006, the company secured a $50.00M Series D investment, with participation from notable investors including Unilever Ventures, CMEA Capital, BioFrontier Partners, Maverick Global Ventures, Mizuho Securities Principal Investment, BSI SA, Sano Ventures, Zesiger Capital, SB Life Science, and Brookside Capital. This strategic investment highlights the confidence of industry leaders in Perlegen Sciences' innovative approach and underscores the potential for significant growth and impact in the biotechnology, health care, and pharmaceutical industries.

Taxonomy: Genetic Insights, Clinical Decisions, Patient Outcomes, Breast Cancer Risk Assessment, Genetic Variations, Clinical Decision-making, Patient Treatment Outcomes, Genotype Browser, Human Populations, Molecular Genetics, Precision Medicine, Genomic Data Analysis, Healthcare Innovation, Medical Research

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $50.00M 10
Unilever Ventures CMEA Capital BioFrontier Partners
Unilever Ventures, CMEA Capital +8
06 Jan 2006
Series D $74.00M -
28 Feb 2005
Series C $30.00M -
28 Jan 2003

Perlegen Sciences Alternatives & Competitors

Perlegen Sciences vs
FullDNA
FullDNA Germany

Preventing Illness before it happens translates into better care

6 employees
Analytics, Biotechnology
Perlegen Sciences vs
Agendia
Agendia United States

MammaPrint® + BluePrint® provides you with actionable insights throughout your patient’s breast canc...

Private Equity
209 employees
Biotechnology, Health Care
Perlegen Sciences vs
NIMGenetics
NIMGenetics Spain

Innovamos en medicina pensando en ti

Venture round
89 employees
Biotechnology, Health Care

FAQ About Perlegen Sciences

Uncovering genetic insights to elevate clinical decisions and enhance patient outcomes.
Perlegen Sciences was founded in 2000.
Perlegen Sciences operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Genetic Insights, Clinical Decisions, Patient Outcomes and Breast Cancer Risk Assessment.
Perlegen Sciences has approximately 17 employees.
Perlegen Sciences has completed 3 funding rounds, raising a total of $154.00M. The latest funding stage is Series D.
Top alternatives and competitors to Perlegen Sciences include FullDNA, Agendia, NIMGenetics, Tempus AI, MNM Bioscience. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Perlegen Sciences and FullDNA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Perlegen Sciences, https://bouncewatch.com/company/perlegen-sciences, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes